Thanks Bavarian a great read appreciated by all. I wonder if AK...

Thanks Bavarian a great read appreciated by all. I wonder if AK will mention anything on the news tonight. I thought the q/a as follows was fascinating ;

‘So it’s a bit early, really, obviously, for acquisition because usually the big pharma only buys after phase two, right?

No, so with CAR Ts, if you look at even in 2022, just recently, they have acquired companies as early as preclinical and early phase one. Two companies that come to mind in particular that got a product or acquired a product for billions, $3.9b and $2 billion respectively, were at the beginning of their phase two and one’s at the end of their phase two.’

I like LC’s choice of words that they “got a product or acquired a product…” which says to me that she sees the opportunity for the commercialisation of products while perhaps still holding other products in the pipeline. That implies to me not selling out the company (but she does mention corporate acquisition up top). Whether IMU will sell a product and thus transfer its ownership or do a development deal is to be seen. We do live in interesting times.